TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia

American Journal of Hematology
Irene M GhobrialJeffrey L Wolf

Abstract

The PI3K/AKT/mTOR signaling pathways are frequently dysregulated in multiple human cancers, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Waldenström's macroglobulinemia (WM). This was the first clinical study to evaluate the safety, tolerability, maximal-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics, and preliminary clinical activity of TAK-228, an oral TORC1/2 inhibitor, in patients with MM, NHL, or WM. Thirty-nine patients received TAK-228 once daily (QD) at 2, 4, 6, or 7 mg, or QD for 3 days on and 4 days off each week (QDx3d QW) at 9 or 12 mg, in 28-day cycles. The overall median age was 61.0 years (range 46-85); 31 patients had MM, four NHL, and four WM. Cycle 1 DLTs occurred in five QD patients (stomatitis, urticaria, blood creatinine elevation, fatigue, and nausea and vomiting) and four QDx3d QW patients (erythematous rash, fatigue, asthenia, mucosal inflammation, and thrombocytopenia). The MTDs were determined to be 4 mg QD and 9 mg QDx3d QW. Thirty-six patients (92%) reported at least one drug-related toxicity; the most common grade ≥3 drug-related toxicities were thrombocytopenia (15%), fatigue (10%), and neutropenia (5%). TAK-228 exhibited a dose-dependent increase in plasma...Continue Reading

Associated Clinical Trials

References

Jul 10, 2003·Cell Cycle·Jiyong Liang, Joyce M Slingerland
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Aug 18, 2006·Nature Reviews. Cancer·David M Sabatini
Nov 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lanie K FrancisIrene M Ghobrial
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josep TaberneroJosé Baselga
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios Athanasios DimopoulosSteven P Treon
Jan 20, 2009·The Journal of Biological Chemistry·Carson C ThoreenNathanael S Gray
Feb 13, 2009·PLoS Biology·Morris E FeldmanKevan M Shokat
Dec 17, 2009·Biochimica Et Biophysica Acta·Ryan J O DowlingNahum Sonenberg
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irene M GhobrialThomas E Witzig
Aug 6, 2010·Blood·Bao HoangAlan Lichtenstein
Sep 10, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Collin Vu, David A Fruman
Dec 16, 2010·Nature Reviews. Molecular Cell Biology·Roberto ZoncuDavid M Sabatini
Jan 11, 2011·Molecular Cancer Therapeutics·Eduardo VilarJosep Tabernero
Jun 3, 2011·The Oncologist·Anas Younes, Nousheen Samad
Oct 4, 2011·Current Opinion in Cell Biology·Eva Dazert, Michael N Hall
Nov 1, 2011·Nature Reviews. Drug Discovery·Don BenjaminMichael N Hall
Nov 3, 2011·Blood·Patricia MaisoIrene M Ghobrial
Jul 11, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naifa L BusaidyLillian L Siu
Feb 13, 2013·Nature Reviews. Clinical Oncology·Jordi RodonJosep Tabernero
May 21, 2013·Cancer Treatment Reviews·Shanthi SivendranMatthew D Galsky
Oct 30, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey I ShapiroGerald Edelman
Dec 10, 2013·Experimental Hematology & Oncology·James SignorovitchPeter Metrakos
Mar 22, 2014·Clinical Lymphoma, Myeloma & Leukemia·Jason R Westin
Aug 31, 2014·Molecular Cancer Therapeutics·Diana CirsteaNoopur Raje
Oct 3, 2014·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J BellmuntI Duran

❮ Previous
Next ❯

Citations

Mar 7, 2014·Journal of Hematology & Oncology·Raoul Tibes, Ruben A Mesa
Feb 2, 2017·British Journal of Haematology·Teresa Calimeri, Andrés J M Ferreri
May 26, 2017·Expert Opinion on Therapeutic Targets·Yoko TabeMarina Konopleva
Mar 7, 2018·Nature Reviews. Clinical Oncology·Filip JankuFunda Meric-Bernstam
Jan 13, 2018·Leukemia & Lymphoma·Vijay Ramakrishnan, Shaji Kumar
Feb 6, 2018·Current Hematologic Malignancy Reports·Helen MaJennifer E Amengual
Mar 11, 2018·Clinical Science·Alberto M MartelliJames A McCubrey
Jun 25, 2019·Current Hematologic Malignancy Reports·Ipsita PalChangchun Deng
Jul 23, 2019·Expert Opinion on Emerging Drugs·Judith LindKlaus Podar
Dec 11, 2019·Cells·Cedric MagawayEstela Jacinto
Feb 22, 2018·Oncotarget·Moran GotesmanDavid A Fruman
May 15, 2018·Oncotarget·Aurelia LamanuzziRoberto Ria
Sep 7, 2019·Oncotarget·Nicci Owusu-BrackettFunda Meric-Bernstam
Jan 16, 2020·Nature Reviews. Molecular Cell Biology·Grace Y Liu, David M Sabatini
Nov 23, 2019·International Journal of Molecular Sciences·Petra Hillmann, Doriano Fabbro
Sep 15, 2020·Exploration of Targeted Anti-tumor Therapy·Joe TaylorGraham Packham
Aug 17, 2018·International Journal of Molecular Sciences·Simone MirabiliiAgostino Tafuri
Apr 25, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sónia R VeigaSara C Kozma
Jul 12, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qi Wen FanWilliam A Weiss
May 18, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·S Lindsey DavisJennifer R Diamond
Feb 24, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qianwen ZhangKer Yu
Aug 8, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xinhua SongXin Chen
Jul 20, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dean C BottinoArijit Chakravarty
Nov 7, 2019·Cell Reports·Helena AspernigAntje Thien
Jan 7, 2021·Cancers·Luca MologniAlfonso Zambon
Nov 1, 2020·Translational Oncology·Anusara DaenthanasanmakThomas A Waldmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.